ETON (Eton Pharmaceuticals) Piotroski F-Score: 4 (As of Aug. 14, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ETON Eton Pharmaceuticals Inc ETON
57 GF Score
Price $58.51
GF Value $19.98
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Eton Pharmaceuticals Piotroski F-Score?

Eton Pharmaceuticals ETON +44.55% 57 Piotroski F-Score is 4 as of Aug. 14, 2026, which is at its 10-year median of 4.00. GuruFocus rates ETON with a GF Score™ of 57/100 and a GF Value™ of $19.98 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 976 Drug Manufacturers companies, Eton Pharmaceuticals ranks worse than 60.86% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Eton Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Eton Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

ETON' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 6
Current: 4

During the past 9 years, the highest Piotroski F-Score of Eton Pharmaceuticals was 6. The lowest was 1. And the median was 4.

Eton Pharmaceuticals  (NAS:ETON) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Eton Pharmaceuticals Piotroski F-Score Related Terms


Eton Pharmaceuticals Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Eton Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eton Pharmaceuticals Piotroski F-Score Chart

Eton Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only 4.00 2.00 5.00 3.00 4.00

Eton Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 4.00 4.00 0.00

ETON vs COLL, ALVO, PCRX: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eton Pharmaceuticals Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Eton Pharmaceuticals's Piotroski F-Score falls into.


ETON
57GF Score
Eton Pharmaceuticals Inc ETON
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was -1.927 + 1.483 + 1.554 + 11.578 = $12.7 Mil.
Cash Flow from Operations was 12.026 + -11.551 + 7.405 + 7.255 = $15.1 Mil.
Revenue was 22.459 + 21.281 + 24.266 + 37.589 = $105.6 Mil.
Gross Profit was 7.855 + 13.1 + 14.735 + 25.413 = $61.1 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(101.676 + 104.51 + 92.114 + 97.71 + 115.807) / 5 = $102.3634 Mil.
Total Assets at the begining of this year (Jun25) was $101.7 Mil.
Long-Term Debt & Capital Lease Obligation was $20.2 Mil.
Total Current Assets was $68.6 Mil.
Total Current Liabilities was $45.1 Mil.
Net Income was 0.627 + -0.598 + -1.572 + -2.585 = $-4.1 Mil.

Revenue was 10.324 + 11.647 + 17.282 + 18.928 = $58.2 Mil.
Gross Profit was 6.302 + 6.476 + 9.861 + 11.924 = $34.6 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(31.823 + 35.841 + 76.123 + 84.032 + 101.676) / 5 = $65.899 Mil.
Total Assets at the begining of last year (Jun24) was $31.8 Mil.
Long-Term Debt & Capital Lease Obligation was $27.9 Mil.
Total Current Assets was $68.4 Mil.
Total Current Liabilities was $38.6 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Eton Pharmaceuticals's current Net Income (TTM) was 12.7. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Eton Pharmaceuticals's current Cash Flow from Operations (TTM) was 15.1. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=12.688/101.676
=0.12478854

ROA (Last Year)=Net Income/Total Assets (Jun24)
=-4.128/31.823
=-0.1297175

Eton Pharmaceuticals's return on assets of this year was 0.12478854. Eton Pharmaceuticals's return on assets of last year was -0.1297175. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Eton Pharmaceuticals's current Net Income (TTM) was 12.7. Eton Pharmaceuticals's current Cash Flow from Operations (TTM) was 15.1. ==> 15.1 > 12.7 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=20.161/102.3634
=0.19695516

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=27.901/65.899
=0.42339034

Eton Pharmaceuticals's gearing of this year was 0.19695516. Eton Pharmaceuticals's gearing of last year was 0.42339034. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=68.599/45.124
=1.52023314

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=68.443/38.596
=1.77331848

Eton Pharmaceuticals's current ratio of this year was 1.52023314. Eton Pharmaceuticals's current ratio of last year was 1.77331848. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Eton Pharmaceuticals's number of shares in issue this year was 32.787. Eton Pharmaceuticals's number of shares in issue last year was 26.893. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=61.103/105.595
=0.57865429

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=34.563/58.181
=0.59405992

Eton Pharmaceuticals's gross margin of this year was 0.57865429. Eton Pharmaceuticals's gross margin of last year was 0.59405992. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=105.595/101.676
=1.038544

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=58.181/31.823
=1.82826886

Eton Pharmaceuticals's asset turnover of this year was 1.038544. Eton Pharmaceuticals's asset turnover of last year was 1.82826886. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Eton Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Eton Pharmaceuticals (ETON) has a Piotroski F-Score of 4 as of Aug. 14, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Eton Pharmaceuticals and its competitors. This is near median its historical median of 4.00. Over the past decade, Eton Pharmaceuticals' Piotroski F-Score has ranged from 1.00 to 6.00. According to the industry distribution chart, Eton Pharmaceuticals ranks #594 out of 976 companies in the Drug Manufacturers industry, placing it in the top 60.9%.
Is Eton Pharmaceuticals' Piotroski F-Score too high?
Eton Pharmaceuticals' current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Eton Pharmaceuticals' value of 4 is 20% below this industry median. Based on the distribution chart, Eton Pharmaceuticals ranks #594 out of 976 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eton Pharmaceuticals has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eton Pharmaceuticals' Piotroski F-Score compare to COLL and ALVO?
According to the Drug Manufacturers industry distribution chart, Eton Pharmaceuticals ranks #594 out of 976 companies for Piotroski F-Score. This places Eton Pharmaceuticals in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Eton Pharmaceuticals' value of 4 is 20% below this benchmark. Historically, Eton Pharmaceuticals' own Piotroski F-Score has ranged from 1.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Eton Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 976 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eton Pharmaceuticals's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Eton Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eton Pharmaceuticals's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eton Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Eton Pharmaceuticals (ETON) is currently considered Significantly Overvalued. The stock's GF Value™ is $19.98, compared to a current price of $58.51 — trading 192.8% above its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Drug Manufacturers industry median of 5.00. Eton Pharmaceuticals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Eton Pharmaceuticals (ETON), the current Piotroski F-Score is 4 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eton Pharmaceuticals (ETON) Overvalued in 2026?

Based on GuruFocus' analysis, Eton Pharmaceuticals stock appears to be overvalued. The current stock price of $58.51 is trading 192.8% above its estimated GF Value™ of $19.98. GuruFocus considers Eton Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ETON:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: $19.98 vs. price of $58.51 (192.8% above fair value)
  • GF Score™: 57/100 with 3 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#594 of 976)

No single metric tells the full story. See the ETON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eton Pharmaceuticals Business Description

Address 21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
57GF Score

Get the complete analysis for ETON

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.51
Price
$19.98
GF Value